04.03.2024 22:18:24 - dpa-AFX: Nektar Therapeutics Q4 Loss decreases, but misses estimates

WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) released Loss for fourth
quarter that decreased from last year but missed the Street estimates.

The company's earnings totaled -$42.08 million, or -$0.22 per share. This
compares with -$59.69 million, or -$0.32 per share, in last year's fourth
quarter.

Analysts on average had expected the company to earn -$0.21 per share, according
to figures compiled by Thomson Reuters. Analysts' estimates typically exclude
special items.

The company's revenue for the quarter rose 8.5% to $23.89 million from $22.02
million last year.

Nektar Therapeutics earnings at a glance (GAAP) :

-Earnings (Q4): -$42.08 Mln. vs. -$59.69 Mln. last year.
-EPS (Q4): -$0.22 vs. -$0.32 last year.
-Revenue (Q4): $23.89 Mln vs. $22.02 Mln last year.


Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
NEKTAR THERAPEUTICS 165417 Frankfurt 1,521 24.05.24 08:03:09 -0,069 -4,34% 0,000 0,000 1,521 1,521

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH